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Objective Our goals were to estimate the placebo and nocebo
responses in restless legs syndrome (RLS).
Methods Databases were searched up to October 2015. Rand-
omised, double-blind, placebo-controlled trials of RLS patient
were included. ‘Placebo response’ was defined as the within-
group change from baseline, using any scale measuring RLS
severity or disability. ‘Nocebo response’ was defined as the
proportion of patients experiencing adverse events in the pla-
cebo arm. Random-effects meta-analysis was used to pool
data.
Results We included 5046 participants. Pooled placebo
response effect size was 1.41 (95%CI:1.56-1.25), corre-
sponding to 6.58 points in the International RLS Study
Group Scale (IRLS). Pooled nocebo response was 45.36%
(95%CI:40.47%–50.29%). The placebo and nocebo responses
were greater in trials with longer duration, evaluating pharma-
cological interventions and idiopathic RLS, and in industry
funded and unpublished studies. The placebo response was
considerable smaller in objective as compared to subjective
outcomes. In addition, the nocebo response increases propor-
tionally with the placebo response, and has the same
predictors.
Conclusions The magnitude of the placebo response in RLS is
above the threshold of minimal clinical important difference,
and the frequency of adverse events is also considerable.
These results are relevant to inform the design and interpreta-
tion of future clinical trials.
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Background/Aim The density of the dopamine transporter
(DAT) continues to decline in the striatum of Parkinson’s dis-
ease (PD) patients, while they get at risk for developing levo-
dopa-induced dyskinesias (LIDs). Here, we studied the role of
DAT-specific imaging as a prognostic marker of dyskinesias.
Methods We retrospectively selected 42 PD patients who had
SPECT imaging with 123I-Ioflupane approximately five years
ago during the diagnosis of PD. 15 patients of them were
rescanned with 123I-Ioflupane SPECT after 6.3±3.0 years. We
divided the PD patients according to the presence or absence
of dyskinesias. SPECT data were analysed for the putamen by
a semi-quantification approach.
Results 10 PD patients had developed LIDs, while 32 were
non-dyskinetic. The putaminal mean 123I-Ioflupane uptake in
the LIDs (1.7±0.4) group was not statistically different as
compared to the non-LIDs group (1.7±0.5;p>010). All 15
PD patients who had a second SPECT scan showed significant
reductions in the putaminal 123I-Iofluplane uptake (p<0.001)
as compared to their first scan. Within this subgroup, the
LIDs (n=8) had significantly lower DAT uptake (1.1±0.3) as
compared to the non-LIDs patients (n=7); (1.5±0.5; p<0.05).
Conclusion 123I-Ioflupane SPECT imaging in de novo PD,
cannot predict the onset of LIDs within five years from diag-
nosis. As shown in the group that repeated 123I-Ioflupane
SPECT imaging, the onset of LIDs may be linked to a faster
decline of putaminal DAT availability.
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Huntington’s disease is an invariably fatal neurodegenerative
disorder characterised by a triad of abnormal movement, pro-
gressive cognitive impairment and psychiatric or behavioural
symptoms. This study looks at 53 patients from The Walton
Centre EnrollHD database. In manifest patients, the most
common presenting symptoms were psychiatric (n=17), fol-
lowed by motor (n=13), cognitive (n=4) and mixed (n=2).
Depression and bipolar disorder were common comorbidities
(n=7, n=11). Of all patients, 29 drank over 14 units; two
drank over 30 units a week. Two had a past medical history
of alcohol abuse. Musculoskeletal comorbidities were more
common in patients who abuse, or have abused alcohol
(p<0.0001). The prevalence of psychiatric, cognitive and
motor symptoms did not vary significantly with alcohol use.
In addition, psychiatric symptoms did not occur earlier when
drinking excessively (46 compared to 41 years old). Obsessiv-
ity, as measured by the Problem Behaviours Assessment, is on
average higher in those that abuse alcohol versus those that
do not drink (7.0 and 2.9 respectively). A one-tailed ANOVA
indicated that this difference was not significant (p>0.05).
The relationship between obsessivity and alcohol abuse is
unclear in this small study sample, although it suggests a
potential relationship between obsession and alcohol abuse.
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Background Half of patients with Parkinson’s disease (PD)
develop dementia. Early detection allows enrichment for clini-
cal trials, but there are no robust clinical markers. Patients
with disease in visual processing regions show greatest risk of
PD dementia. However current visuo-perception tests are
poorly sensitive. We present a sensitive online visuo-perceptual
test based on skewed images of cats and dogs.
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